Trial Profile
Open-label, Single-center Phase II Study of MLN9708 (Ixazomib) in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary)
- Indications T-cell lymphoma
- Focus Therapeutic Use
- 01 Dec 2017 Results assessing the effects of ixazomib on NF-kappaB activity, GATA-3 expression, and cell viability, published in the American Journal of Hematology
- 10 Oct 2017 Status changed from active, no longer recruiting to completed.
- 15 Dec 2016 Status changed from recruiting to active, no longer recruiting.